Evidence map›Paper›PMID 35632624›Full record

ArticleViruses2022

Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients.

Florian D Hastert, Lisa Henss, Christine von Rhein, Julia Gerbeth, Imke Wieters, Frauke Borgans, Yascha Khodamoradi, Kai Zacharowski, Gernot Rohde, Maria J G T Vehreschild and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Florian D HastertDepartment of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany.ORCID 0000-0001-9961-5766
Lisa HenssDepartment of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany.
Christine von RheinDepartment of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany.
Julia GerbethDepartment of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany.
Imke WietersZentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Frauke BorgansZentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Yascha KhodamoradiZentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.ORCID 0000-0001-5972-0967
Kai ZacharowskiKlinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Gernot RohdeMedizinische Klinik 1, Pneumologie/Allergologie, Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-5193-7755
Maria J G T VehreschildZentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
Barbara S SchnierleDepartment of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany.ORCID 0000-0001-9563-4564
Goethe University Frankfurt · DEPaul Ehrlich Institut · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has now been continuing for more than two years. The infection causes COVID-19, a disease of the respiratory and cardiovascular system of variable severity. Here, the humoral immune response of 80 COVID-19 patients from the University Hospital Frankfurt/Main, Germany, was characterized longitudinally. The SARS-CoV-2 neutralization activity of serum waned over time. The neutralizing potential of serum directed towards the human alpha-coronavirus NL-63 (NL63) also waned, indicating that no cross-priming against alpha-coronaviruses occurred. A subset of the recovered patients (

Indexed as

COVID-19COVID-19 VaccinesImmunity, HumoralAntibodies, NeutralizingAntibodies, ViralHumansLongitudinal StudiesmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticDeltaneutralizationNL63OmicronSARS-CoV-1SARS-CoV-2vaccination

Identifiers

PMID35632624
PMCPMC9144377
OpenAlexW4224325061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.